Special Issue

Multimodal Approaches to Diagnosing Metabolic Bone Diseases

Message from the Guest Editors

Metabolic bone diseases encompass a diverse group of disorders, ranging from inherited to acquired conditions, which share a common disruption in the balance between bone formation and resorption and carry significant morbidity and mortality when misdiagnosed.

Due to their complex nature, metabolic bone diseases often require a multimodal and multidisciplinary approach to diagnosis and management that relies on close teamwork among clinicians, radiologists, pathologists, and geneticists. Recent advances in sensitive diagnostic and prediction methods, such as emerging biomarkers, new or integrated imaging techniques, machine learning, and computer-based diagnosis have been proven to represent a useful tool for supporting a physician during the diagnostic process. In this landscape, multimodal approaches that enable the deep phenotyping of patients are crucial to advance precision medicine and ensure early/accurate diagnosis, leading to better treatment and outcomes.

Guest Editors


Dr. Simona D'Amore

Dr. Antonio G. Solimando

Dr. Uma Ramaswami

Deadline for manuscript submissions

closed (31 May 2025)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/196270

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

